Women undergoing mastectomy did not have an accurate idea of their future well-being, with misprediction associated with greater regret but not satisfaction with decisions.
A single infusion of the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel produced durable remissions in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic lymphoma.
The US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults.
Patients with head and neck cancer who had depressive symptoms at the time of treatment planning had worse overall 2-year mortality.
Venetoclax had promising clinical activity in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with idelalisib.
Use of stereotactic ablative radiotherapy effectively treated patients with primary renal cell carcinoma and had an acceptable effect on patient renal function.
The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with bone metastases and multiple myeloma.
Two years of maintenance chemotherapy with rituximab resulted in improved progression-free survival among elderly patients with chronic lymphocytic leukemia.
Undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in improved overall survival compared with resection alone for patients with gastric cancer with peritoneal carcinomatosis, according to data presented at the 2018 Gastrointestinal Cancers Symposium.
Patients assigned to robot-assisted minimally invasive thoraco-laparoscopic esophagectomy had fewer overall, surgery-related, and cardiopulmonary complications compared with open transthoracic esophagectomy, according to the results of the ROBOT trial.